Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Published by: Amity Research Centers
Published in: 2019
Length: 13 pages
Data source: Published sources

Abstract

Despite being among the top healthcare concerns, McKesson Corporation (McKesson) largely remained unknown as far as the US business fraternity was concerned. Still, the company thrived in its pursuit of being a top healthcare and pharma logistics company with several business operations. With nearly USD200 billion in annual revenues, it was arguably the fifth-largest company in America. Having a comprehensive revenue stream powered by some unique business segments, the company' operations had been far and wide. It was claimed to have made ample contribution towards addressing public health emergency, environmental issues, disaster mitigation and so on, while marching ahead to set a precedent in the realm of business sustainability. But the company had to face some seemingly grave challenges like the one concerning the alleged mishandling of the opioid epidemic, whereupon it had to face huge financial loss on top of litigations. Another upcoming challenge was the existing Chairman and CEO John H Hammergren's (Hammergren) retirement due in March 2019. Could the company continue its march with what it called a sustainable business? Could the new CEO and Chairman carry the legacy created by Hammergren by virtue of his relentless drive towards ensuring sustainability?

Teaching and learning

This item is suitable for undergraduate, postgraduate and executive education courses.

Time period

The events covered by this case took place in 2018.

Geographical setting

Region:
Americas
Country:
United States
Location:
California

Featured company

McKesson Corporation
Employees:
10000+
Turnover:
USD 200 billion
Type:
Partnership

Featured protagonist

  • John H. Hammergren (male), Chairman and CEO

About

Abstract

Despite being among the top healthcare concerns, McKesson Corporation (McKesson) largely remained unknown as far as the US business fraternity was concerned. Still, the company thrived in its pursuit of being a top healthcare and pharma logistics company with several business operations. With nearly USD200 billion in annual revenues, it was arguably the fifth-largest company in America. Having a comprehensive revenue stream powered by some unique business segments, the company' operations had been far and wide. It was claimed to have made ample contribution towards addressing public health emergency, environmental issues, disaster mitigation and so on, while marching ahead to set a precedent in the realm of business sustainability. But the company had to face some seemingly grave challenges like the one concerning the alleged mishandling of the opioid epidemic, whereupon it had to face huge financial loss on top of litigations. Another upcoming challenge was the existing Chairman and CEO John H Hammergren's (Hammergren) retirement due in March 2019. Could the company continue its march with what it called a sustainable business? Could the new CEO and Chairman carry the legacy created by Hammergren by virtue of his relentless drive towards ensuring sustainability?

Teaching and learning

This item is suitable for undergraduate, postgraduate and executive education courses.

Settings

Time period

The events covered by this case took place in 2018.

Geographical setting

Region:
Americas
Country:
United States
Location:
California

Featured company

McKesson Corporation
Employees:
10000+
Turnover:
USD 200 billion
Type:
Partnership

Featured protagonist

  • John H. Hammergren (male), Chairman and CEO

Related